Reshma Kewalramani, born in Mumbai and now CEO of Vertex Prescription drugs, has earned a coveted spot on Fortune’s 2025 listing of the 100 Most Highly effective Individuals in Enterprise. Ranked at quantity 62, she is the one Indian-origin lady CEO of a serious US biotechnology firm to make this 12 months’s listing. Whereas international names like Mark Zuckerberg, Sundar Pichai, Satya Nadella, and Mukesh Ambani additionally seem on the listing, Kewalramani’s recognition marks a monumental achievement for ladies in science-led industries. Her rise from a doctor in Boston hospitals to the helm of a $110 billion biotech firm is a outstanding journey of management, innovation, and influence within the international healthcare panorama.
Who’s Reshma Kewalramani: The Mumbai-born biotech CEO on Fortune’s 2025 Most Highly effective Enterprise Leaders listing
Born in Mumbai, Reshma Kewalramani moved to america when she was simply 11 years previous. With a ardour for medication, she pursued her training and commenced her profession as a doctor at Massachusetts Basic Hospital and Brigham and Ladies’s Hospital—two of probably the most prestigious medical establishments within the US. Her early experiences in medical settings laid a powerful basis for her future in biotechnology, the place patient-centered care and scientific innovation go hand in hand.In 2020, Reshma Kewalramani made historical past by turning into the primary lady to guide a serious US biotechnology firm. She joined Vertex Prescription drugs in 2017 and shortly ascended the ranks—turning into Chief Medical Officer in 2018 after which CEO simply two years later. Her appointment was greater than a private milestone—it symbolized a breakthrough in gender illustration in a area historically dominated by males, particularly on the government degree.
Vertex Prescription drugs grows to $110 billion underneath Reshma Kewalramani
Below her management, Vertex Prescription drugs has grown right into a biotech powerhouse valued at $110 billion. The corporate is thought for its improvements in treating cystic fibrosis and continues to increase its pipeline with daring analysis in uncommon ailments. Most notably in 2025, the corporate obtained FDA approval for Journavx, a revolutionary non-opioid ache therapy. This approval is being hailed as a landmark within the international combat towards the opioid epidemic—a disaster that has devastated tens of millions.Kewalramani’s distinctive edge as a licensed doctor provides her a twin perspective—scientific and strategic. In contrast to many biotech CEOs who come from a purely enterprise background, she brings hands-on medical expertise to boardroom selections. This medical perception has been essential in shaping Vertex’s patient-first method to drug improvement and innovation, additional elevating its international credibility and influence.
Reshma Kewalramani ranks 62 on Fortune’s influential enterprise leaders listing
Now in its second version, Fortune’s 100 Most Highly effective Individuals in Enterprise celebrates people who wield affect, drive innovation, and form the way forward for business—not merely these with the very best web value. Kewalramani’s entry at rank 62 is a transparent indication of her rising stature within the worldwide enterprise and biotech communities.The highest ranks this 12 months function:
- Jensen Huang (CEO of Nvidia) – Rank 1
- Satya Nadella (CEO of Microsoft) – Rank 2
- Sundar Pichai (CEO of Google) – Rank 6
- Mukesh Ambani (Chairman of Reliance Industries) – Rank 56
- Neal Mohan (CEO of YouTube) – Rank 83
- Gautam Adani (Industrialist) – Rank 96
Whereas Reshma Kewalramani could not but be a family identify, her work is remodeling lives. Her quiet however impactful management model focuses on significant science, international well being, and numerous illustration in management. That is her first time on the Fortune listing, and it signifies international acknowledgment of her contributions not simply to enterprise, however to humanity by means of science.Additionally Learn | Earthquake risk in Canada! Yukon fault shows signs of awakening after 12,000 years, threatening thousands
